NASD · Healthcare · Biotechnology · USA
Codexis Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Codexis develops enzymatic tools and processes using its CodeEvolver technology platform to improve manufacturing of therapeutics. The company operates two main business segments: its ECO Synthesis platform, which provides enzymes and manufacturing services for RNA interference therapeutics, and its small molecule pharma biocatalysis business, which supplies optimized enzymes to pharmaceutical companies for efficient production of small molecule drugs.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Codexis Inc stock.
Slightly undervalued: intrinsic value $1.52 per share, market price $1.23, margin of safety 19.3% (as of 2026-10-20).
A 2.0x revenue multiple, discounted for its losses, values the shares at $1.52; the price of $1.23 is 19% below that value.
Leak Score: 36/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
15 more in this industry show a wider margin of safety.
CDXS is slightly undervalued (as of the 2026-10-20 close). A 2.0x revenue multiple, discounted for its losses, values the shares at $1.52; the price of $1.23 is 19% below that value.
$1.52 per share (as of the 2026-10-20 close), against a market price of $1.23. That is a margin of safety of 19.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
36 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.